Photocure agreed to acquire Vesica Health for $30.5 million in cash and stock, adding AssureMDx—Vesica’s urine-based molecular test for early bladder cancer detection—to its portfolio. The acquisition expands Photocure’s reach into hematuria risk stratification, moving beyond its current cystoscopy-linked non-muscle invasive bladder cancer offerings. AssureMDx uses methylation-specific PCR and next-generation sequencing to analyze biomarkers from urine, with reported performance metrics including 96% sensitivity and 99.7% negative predictive value. It also holds Breakthrough Device Designation and has been incorporated into American Urological Association guidance for microhematuria evaluation. The deal includes a structure tied to Medicare reimbursement milestones, indicating payor pathway importance for commercialization and adoption in urology settings.